A Multicentre Randomized Double-blinded Placebo-controlled Parallel Group Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants with Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Brief description of study

The purpose of this study is to test if a single dose of nerinetide can reduce neurological disability in people who have had a stroke and who are selected for endovascular therapy. Nerinetide is an investigational drug being developed as an emergency medication aimed at preventing damage to brain cells during a stroke. “Investigational” means that the drug is being tested in a research study and is not approved by the U.S. Food and Drug Administration (FDA) to treat your condition. Nerinetide acts by blocking a protein in the brain responsible for cell damage during a stroke. The safety of nerinetide has been tested previously in healthy people and in patients having strokes.


Clinical Study Identifier: s20-01858
ClinicalTrials.gov Identifier: NCT04462536
Principal Investigator: David Turkel-Parrella.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.